Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 798

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 798
---
 or trademark (or service mark) registration; |

| d. | whether property identified as a trade secret is, in fact, a legally enforceable trade secret, and the scope of protection afforded; |

| e. | the scope of patent claims; that is, the range and types of products or processes covered by any patent; |

| f. | whether the inventor(s) identified in any patent is(are) the true inventor(s), and whether all inventors have been named; |

| g. | the scope of rights in trademarks, service marks or trade names; |

| h. | the correct authorship of any copyrighted works; |

| I. | whether there has been litigation relating to such intangible assets and the results of any adjudication or settlement of such litigation, particularly with respect to issues of validity, enforceability and scope of protection afforded. |

M&N has not been involved in the financial planning, the structuring of the ownership entity(s), and/or the tax and accounting issues related to any Federal Gift and/or Estate Tax Planning Strategy. Furthermore, we have provided no legal advice and we take no responsibility for the legal interpretation of California Partnership Law, or the Laws of any other state impacting the entity(s) valued herein. In addition, if any adjustments have been made for the lack of control or the lack of marketability in the appraisal, then that segment of our analysis is not in compliance with the Uniform Standards of Professional Appraisal Practice (“USPAP”), in that USPAP does not specifically reference any methodology for valuing minority interests in Partnerships, Corporations, LLCs, etc. or undivided fractional interests held directly in real estate. The liability of M&N and its employees and associates is limited to the Client only and to the amount of the fee actually received by M&N. There is no accountability, obligation, or liability to any third party. If the Opinion or any part thereof is disseminated to anyone other than the Client, the Client shall make such party or parties aware of all limiting conditions and assumptions affecting the appraisal assignment. [REMAINDER OF THIS PAGE LEFT INTENTIONALLY BLANK]

F-8

#### TABLE OF CONTENTS

#### Annex G

### FORM OF LOCK-UP AGREEMENT
[ • ], 2025

Channel Therapeutics Corporation

4400 Route 9 South, Suite 1000

Freehold, NJ 07728

Ladies and Gentlemen:

The undersigned signatory of this lock-up agreement (this “